FI944821A - Galantamiinijohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö lääkeaineissa - Google Patents

Galantamiinijohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö lääkeaineissa Download PDF

Info

Publication number
FI944821A
FI944821A FI944821A FI944821A FI944821A FI 944821 A FI944821 A FI 944821A FI 944821 A FI944821 A FI 944821A FI 944821 A FI944821 A FI 944821A FI 944821 A FI944821 A FI 944821A
Authority
FI
Finland
Prior art keywords
hydrogen
drugs
preparation
alkylaminocarbonyl
alkyl
Prior art date
Application number
FI944821A
Other languages
English (en)
Swedish (sv)
Other versions
FI944821A0 (fi
FI108723B (fi
Inventor
Jr Raymond J Kosley
Larry Davis
Veronica Taberna
Original Assignee
Hoechst Roussel Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Roussel Pharma filed Critical Hoechst Roussel Pharma
Publication of FI944821A0 publication Critical patent/FI944821A0/fi
Publication of FI944821A publication Critical patent/FI944821A/fi
Application granted granted Critical
Publication of FI108723B publication Critical patent/FI108723B/fi

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10Spiro-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/06Peri-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI944821A 1993-10-15 1994-10-13 Menetelmä terapeuttisesti käyttökelpoisten 4a,5,9,10,11,12-heksahydro-11-metyyli-6H-bentsofuro[3a,3,2-ef][2]bentsatsepiini-3,6-diolin 6-esterijohdannaisten valmistamiseksi FI108723B (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13744093 1993-10-15
US08/137,440 US6323195B1 (en) 1993-10-15 1993-10-15 Galanthamine derivatives as acetylcholinesterase inhibitors

Publications (3)

Publication Number Publication Date
FI944821A0 FI944821A0 (fi) 1994-10-13
FI944821A true FI944821A (fi) 1995-04-16
FI108723B FI108723B (fi) 2002-03-15

Family

ID=22477446

Family Applications (1)

Application Number Title Priority Date Filing Date
FI944821A FI108723B (fi) 1993-10-15 1994-10-13 Menetelmä terapeuttisesti käyttökelpoisten 4a,5,9,10,11,12-heksahydro-11-metyyli-6H-bentsofuro[3a,3,2-ef][2]bentsatsepiini-3,6-diolin 6-esterijohdannaisten valmistamiseksi

Country Status (23)

Country Link
US (2) US6323195B1 (fi)
EP (2) EP0653427B1 (fi)
JP (1) JP2664344B2 (fi)
KR (1) KR0169114B1 (fi)
CN (1) CN1039911C (fi)
AT (1) ATE212348T1 (fi)
AU (1) AU696249B2 (fi)
CA (1) CA2118174C (fi)
CZ (1) CZ287071B6 (fi)
DE (1) DE69429708T2 (fi)
DK (1) DK0653427T3 (fi)
EG (1) EG20472A (fi)
ES (1) ES2171428T3 (fi)
FI (1) FI108723B (fi)
IL (1) IL111274A (fi)
NO (1) NO310415B1 (fi)
NZ (1) NZ264683A (fi)
PL (1) PL177730B1 (fi)
PT (1) PT653427E (fi)
RO (1) RO114133B1 (fi)
RU (1) RU2114850C1 (fi)
TW (1) TW363969B (fi)
ZA (1) ZA948062B (fi)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514821D0 (en) * 1995-07-19 1995-09-20 Sod Conseils Rech Applic Galanthamine derivatives
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
EP1133230A4 (en) * 1998-11-23 2004-05-26 Bonnie M Davis DOSAGE FORMULAS FOR ACETYLCHOLINESTERASE INHIBITORS
DE69912311T2 (de) 1998-12-24 2004-07-29 Janssen Pharmaceutica N.V. Galantamin-zusammensetzung mit gesteuerter freisetzung
US8603546B2 (en) * 1999-01-11 2013-12-10 Herbaceuticals Inc. Herbal supplement for increased muscle strength and endurance for athletes
EP1150695B1 (en) * 1999-01-11 2007-02-28 Atanas Russinov Djananov Herbal supplement for increased muscle strength and endurance for athletes
DK1086706T3 (da) * 1999-03-31 2004-03-08 Eisai Co Ltd Stabiliserede sammensætninger indeholdende nootropiske lægemidler
WO2001030318A1 (en) * 1999-10-26 2001-05-03 Janssen Pharmaceutica N.V. Oral solution containing galanthamine and a sweetening agent
EP1237524A4 (en) * 1999-12-10 2004-06-30 Bonnie M Davis GALANTHAMINE AND LYCORAMINE ANALOGS FOR USE AS MODULATORS OF NICOTINIC RECEPTORS
CZ300160B6 (cs) 2000-03-31 2009-02-25 Sanochemia Pharmazeutika Aktiengesellschaft Deriváty galanthaminu, zpusob výroby techto derivátu, lécivo, které tyto deriváty obsahuje, použitítechto derivátu pro výrobu léciva, zpusob výroby tohoto léciva a zpusob separace (+)- a (-)-izomeruuvedených derivátu
US20030162770A1 (en) * 2002-02-22 2003-08-28 Davis Bonnie M. Use of modulators of nicotinic receptors for treatment of cognitive dysfunction
US20050143350A1 (en) * 2003-11-19 2005-06-30 Seed John C. Combination drug therapy to treat obesity
CA2551946A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Immediate, controlled and sustained release formulations of galantamine
WO2005065662A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
US20080045500A1 (en) * 2004-07-01 2008-02-21 Eisai R&D Management Co., Ltd. Nerve Regeneration Stimulator
US8632800B2 (en) * 2005-05-13 2014-01-21 Alza Corporation Multilayer drug delivery system with barrier against reservoir material flow
US20080188510A1 (en) * 2005-05-23 2008-08-07 Eisai R & D Management Co., Ltd. Novel methods using zonisamide
EP1777222A1 (en) * 2005-09-22 2007-04-25 Galantos Pharma GmbH Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
ATE473219T1 (de) * 2005-09-22 2010-07-15 Galantos Pharma Gmbh Cholinerge enhancer mit verbesserter durchgängigkeit durch die blut-hirn-schranke zur behandlung von krankheiten, die mit kognitiven störungen einhergehen
US20090253654A1 (en) 2005-09-22 2009-10-08 Galantos Pharma Gmbh Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment
US20070104771A1 (en) * 2005-09-23 2007-05-10 Jay Audett Transdermal galantamine delivery system
DK2137192T3 (da) 2008-04-14 2014-05-26 Neurodyn Life Sciences Inc Derivater af galantamin som prodrugs til behandling af humane hjernesygdomme
EP2456434A1 (en) * 2009-07-23 2012-05-30 Shire LLC Galantamine amino acid and peptide prodrugs and uses thereof
WO2013160728A1 (en) 2012-04-26 2013-10-31 Alma Mater Studiorum - Universita' Di Bologna Dual targeting compounds for the treatment of alzheimer's disease
EP3628315A1 (en) 2018-09-28 2020-04-01 Université de Caen Normandie Combination of acetylcholinesterase inhibitor and 5-ht4 receptor agonist as neuroprotective agent in the treatment of neurodegenerative diseases
CN113292420A (zh) * 2021-05-27 2021-08-24 神隆医药(常熟)有限公司 加兰他敏中间体原料2-溴-5-羟基-4-甲氧基苯甲酸回收方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL122665B1 (en) 1978-11-21 1982-08-31 Edinen Zentar Chim Process for preparing novel dienones of narvedine type and their derivatives
US4663318A (en) 1986-01-15 1987-05-05 Bonnie Davis Method of treating Alzheimer's disease
US6150354A (en) * 1987-01-15 2000-11-21 Bonnie Davis Compounds for the treatment of Alzheimer's disease
JP2755403B2 (ja) * 1987-05-04 1998-05-20 デイービス、ボニー アルツハイマー病の治療のための化合物
NL8800350A (nl) 1988-02-12 1989-09-01 Stichting Biomedical Research Synthetische galanthamine-derivaten, werkwijze voor het bereiden daarvan, en farmaceutische samenstellingen.
WO1992020327A1 (en) 1991-05-14 1992-11-26 Ernir Snorrason Treatment of fatigue syndrome with cholinesterase inhibitors
US5153193A (en) 1991-10-01 1992-10-06 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs
US5231093A (en) * 1991-10-01 1993-07-27 Hoechst-Roussel Pharmaceuticals Incorporated Carbamate derivatives of 4-amino-3-isoxazolidinones, 3-amino-1-hydroxypyrrolidin-2-ones and 1-amino-1-cyclopropanecarboxylic acid analogs

Also Published As

Publication number Publication date
IL111274A (en) 2000-11-21
EP1020470A2 (en) 2000-07-19
PL305456A1 (en) 1995-04-18
EP0653427A1 (en) 1995-05-17
EP1020470A3 (en) 2000-07-26
RO114133B1 (ro) 1999-01-29
NZ264683A (en) 1998-03-25
FI944821A0 (fi) 1994-10-13
NO943893L (no) 1995-04-18
ATE212348T1 (de) 2002-02-15
CN1111245A (zh) 1995-11-08
AU7581494A (en) 1995-05-04
NO943893D0 (no) 1994-10-14
DE69429708D1 (de) 2002-03-14
KR950011443A (ko) 1995-05-15
DE69429708T2 (de) 2002-08-29
JP2664344B2 (ja) 1997-10-15
ES2171428T3 (es) 2002-09-16
PT653427E (pt) 2002-06-28
EP0653427B1 (en) 2002-01-23
IL111274A0 (en) 1994-12-29
US6323195B1 (en) 2001-11-27
CA2118174A1 (en) 1995-04-16
CA2118174C (en) 2000-01-18
PL177730B1 (pl) 2000-01-31
JPH07188240A (ja) 1995-07-25
US5777108A (en) 1998-07-07
FI108723B (fi) 2002-03-15
CN1039911C (zh) 1998-09-23
RU2114850C1 (ru) 1998-07-10
CZ287071B6 (en) 2000-08-16
TW363969B (en) 1999-07-11
EG20472A (en) 1999-05-31
RU94036448A (ru) 1996-09-10
NO310415B1 (no) 2001-07-02
AU696249B2 (en) 1998-09-03
CZ254694A3 (en) 1995-09-13
KR0169114B1 (ko) 1999-01-15
ZA948062B (en) 1995-06-06
DK0653427T3 (da) 2002-04-15

Similar Documents

Publication Publication Date Title
FI944821A (fi) Galantamiinijohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö lääkeaineissa
CA2092794A1 (fr) Naphtylalkylamines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
MY131501A (en) Process for the prepration of clavulanic acid
FI944822A0 (fi) Galantamiinijohdannaisia, menetelmä niiden valmistamiseksi ja niiden käyttö lääkeaineissa
IL110151A0 (en) Amide and urea derivatives and pharmaceutical compositions containing the same
FI103046B1 (fi) Menetelmä lääkeaineina käyttökelpoisten pyrrolidinyylitiokarbapeneemijohdannaisten valmistamiseksi
DE69330601D1 (de) Serotoninergische ergolin derivate
NO953557L (no) Antitumorpreparater og fremgangsmåte for deres fremstilling
GB2282810A (en) Process for the preparation of clavulanic acid

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: HOECHST MARION ROUSSEL, INC.

PC Transfer of assignment of patent

Owner name: AVENTISUB II INC.

Free format text: AVENTISUB II INC.

MA Patent expired